Sertraline treatment for 6 weeks significantly reduced platelet secretion in response to collagen among patients with major depressive episodes.
Does sertraline reduce platelet activation in patients with untreated major depressive episodes?
Sertraline treatment significantly attenuates increased platelet activation in patients with major depression, suggesting a potential mechanism for cardiovascular risk reduction in this population.
OBJECTIVE: The authors' goal was to determine whether sertraline attenuates the increased platelet activation seen among depressed patients. METHOD: They tested 21 otherwise healthy patients with untreated major depressive episode who were 25-52 years old and 21 age- and sex-matched comparison subjects. Patients received 6 weeks of sertraline treatment, and 17 returned for retesting. RESULTS: At baseline, the depressed patients had greater platelet secretion than the comparison subjects in response to collagen. Depressed patients with a family history of coronary disease had nonsignificantly greater wound-induced fibrinogen receptor binding than the other subjects. Platelet secretion in response to collagen was significantly reduced after treatment with sertraline. CONCLUSIONS: Sertraline diminished the increased platelet secretion found among depressed patients, although the findings are limited by a lack of a placebo control group.
Markovitz et al. (Thu,) conducted a other in Major depressive episode (n=42). Sertraline vs. Healthy comparison subjects and pre-treatment baseline was evaluated on Platelet secretion in response to collagen. Sertraline treatment for 6 weeks significantly reduced platelet secretion in response to collagen among patients with major depressive episodes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: